Tell Your Dad - Armune BioScience
Transcription
Tell Your DadSM June is Men’s Health Month Men need to be reminded about the importance of early detection to treat serious diseases Step-up! Tell Your DadSM 3 important things about his health Copyright © 2008-2015, Armune BioScience, Inc. June is Men’s Health Month Dads often get labeled as poor listeners at home. Dads will listen to their daughters. Daughters, it is time to Step-up and Tell Your DadSM 3 important things for his health. 1 Tell Your DadSM About his risk for Prostate Cancer1 • Prostate cancer is the #1 non-skin cancer among men. • In 2015, the estimates for prostate cancer in the United States are: ■■ About 220,800 new cases of prostate cancer ■■ About 27,540 deaths from prostate cancer • About 1 man in 7 will be diagnosed with prostate cancer during his lifetime. • African-American men are more than twice as likely to die of prostate cancer as white men. • Tell your dad to talk with his physician about his risk for prostate cancer and determine if screening for prostate cancer is appropriate for him.2 2 Tell Your DadSM About Apifiny™ • Apifiny is a cancer specific blood test that measures the body’s immune system response to prostate cancer. • Apifiny is the only cancer specific, non-PSA blood test available in the world that may aid clinicians in the detection of prostate cancer. Apifiny™ Prostate Cancer Lower Risk 0 59 Higher Risk 100 Risk Assessment 3 Tell Your DadSM To ask his physician if Apifiny™ is right for him • Shared decision making 2 between your dad and his clinician is an important part of his overall healthcare. • If your dad has an elevated PSA (>2.5 ng/ml) and is considering a prostate biopsy, Apifiny may help him and his clinician decide if a biopsy is the most appropriate next step in his care. • Make sure your dad is prepared to have a productive discussion with his physician about his risk for prostate cancer. 1. www.cancer.org/cancer/prostatecancer 2. www.auanet.org/education/guidelines/prostate-cancer-detection The only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer Apifiny™ Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment Does your dad know his Apifiny™ Score? Armune BioScience, Inc. 401 West Morgan Road Ann Arbor, MI 48108 Toll Free Helpline: 844-427-6863 www.armune.com 06/15
Similar documents
Manual Gratification and Prostate Health - Could This Be the Link to Fighting Prostate Cancer
More information
Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market
Prostate cancer market was valued at $2.6 billion in 2013 and it is expected to reach $8.3 million, by 2023. It is estimated that the market will grow at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer.
More informationHormone Sensitive Prostate Cancer Market Segments, Opportunity, Growth and Forecast by End-use Industry 2016-2026
Prostate cancer is a general term used for diseased condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (i.e. androgens) and ultimately blocks the action of androgen. The androgen is also responsible for the growth of prostate cancer. Androgen binds with the receptors and stimulates the expression of specific genes that would be responsible for prostate cancer. However, androgen suppression hormonal therapies are commonly used for the treatment of this cancer. These therapies acts by reducing the production of androgen by the testicles or by blocking the action of androgen in the body. There is an opportunity for the growth of hormone sensitive prostate cancer owing to the rapidly aging population which is the major cause of prostate cancer.
More information